Top Markets
Coin of the day
GenSight Biologics S.A. GenSight Biologics S.A.

GenSight Biologics S.A.

SIGHT
Rang in Aktien #29796
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Aktienkurs
$0.12027613
Marktkapitalisierung
$19.61M
Veränderung (1 Tag)
-3.06%
Veränderung (1 Jahr)
-40.33%
Land
FR
Handel GenSight Biologics S.A. (SIGHT)

Kategorie

Kursverlauf für GenSight Biologics S.A. (SIGHT)
Höchster Schlusskurs: $0.11 am 2026-08-01

Niedrigster Schlusskurs: $8.93 am 2016-07-01
Kursverlauf der Aktie von GenSight Biologics S.A. von 2016 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 0.82%
2025 -61.96%
2024 -40.41%
2023 -85.79%
2022 -40.62%
2021 -23.84%
2020 252.34%
2019 -43.91%
2018 -36.71%
2017 -20.44%
2016 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$527.89 35.09%
US
$996.61 51.72%
NL
$117.42 -19.34%
AU
$742.10 6.97%
CH
$1.07K -5.58%
KR